Objective: To determine the cholesterol-lowering efficacy of hydroxypropylmethylcellulose (HPMC) , and 12 and 15% at 15 g day À1 , respectively, over placebo. Adverse effects were minimal. Trial one: medium, high and ultra-high viscosity HPMC at 15 g day À1 for 1 week each; 1-week wash-out between treatments. Trial two: ultra-high viscosity HPMC at 5 or 15 g day À1 for 8 weeks. Conclusions: HPMC soluble fiber, especially high-viscosity grades, significantly lowers cholesterol at well-tolerated doses, showing promise as a treatment of hypercholesterolemia.
Introduction
Hydroxypropylmethylcellulose (HPMC) and methylcellulose are produced from cellulose, a carbohydrate with a repeating structure of anhydroglucose units. These food gums are a good source of soluble fiber and are approved for food use in the USA; an AOAC 2006.08 analytical method has been developed and validated for their analysis Harfmann et al., 2007; Turowski et al., 2007) . They are safe food additives without appreciable adverse effects (McCollister et al., 1973; Nitschke and Fiero, 1977; Santos, 1986) , undergoing no significant digestion or fermentation in the gut of animals (Braun et al., 1974; Yokoyama et al., 2002) or humans (Machle et al., 1944) .
HPMC can potentially regulate blood cholesterol, a key factor in cardiovascular disease. Methylcellulose and HPMC are known to lower cholesterol in animals (Benko et al., 1970; Gallaher et al., 1993a, b; Carr et al., 1996) . Six clinical trials have investigated HPMC treatment in healthy and hypercholesterolemic humans either short-term, or longterm at low dosages (Dressman et al., 1993; Swidan et al., 1996; Maki et al., 1999 Maki et al., , 2000 . This paper reports two further clinical trials with HPMC in mildly hypercholesterolemic humans: a 'mechanism' study investigating the role of viscosity in HPMC serum cholesterol reduction, and a 'long-term' study investigating cholesterol lowering by ultra-high viscosity HPMC.
Subjects and methods
Study site and subject screening Clinical trials were conducted at the Clinical Research Center of The University of Michigan Hospitals with approval from the Institutional Review Board for Studies Involving Human Subjects and from the Food and Drug Administration. Informed consent was obtained from each subject.
Subjects were assessed according to age, weight and ability to comply with the protocols. They were screened for health/ disease, and use of medications, alcohol and tobacco. Blood was assessed for electrolyte balance, kidney and liver function and blood morphology and lipids. The required entry concentrations for the mechanism study were 5.18 mmol l ). Women of childbearing age were screened for pregnancy and instructed to use birth control during the study.
Mechanism study
Of the 12 subjects, eight were women with mean age 39.5 (range, 29-59) years, mean total cholesterol 6.48 (range, 5.57-7.51 ) total cholesterol and 94.5 (range, 84.5-106.8) kg.
There were four 1-week study phases, with a 1-week washout period between phases. In each phase-administered according to a randomized, single-blind, crossover design-subjects consumed 250 ml of a sugar-free gelatin dessert containing either 5 g HPMC (test phases) or no HPMC (placebo phase). The gelatin dessert was consumed during breakfast, lunch and dinner, for a total of 15 g of HPMC per day during each test phase.
Viscosities (measured according to the United States Pharmacopeia, 2003) of the gelatin dessert from the four phases were: placebo gelatin (0.3 cP), medium-viscosity HPMC (3915 cP), high-viscosity HPMC (22 703 cP) and ultra-high viscosity HPMC (63 030 cP). All HPMC products (The Dow Chemical Company, Midland, MI, USA) were food grade and complied with the monograph Hypromellose Type 2208 (United States Pharmacopeia, 2003) .
Food intake was controlled throughout the mechanism study to ensure that the only dietary difference between groups was the presence or absence of HPMC. Subjects ate all meals at the General Clinical Research Center, selecting meals corresponding to their usual diet. In study week 1, all food consumed was inventoried. In subsequent phases, the types and quantities of food consumed were reproduced.
On days 1 and 8 of each phase, following an overnight fast, weight, vital signs and serum lipids were measured. Electrolytes, hepatic and renal function and blood morphology were measured on the first and last study days.
The effect of HPMC on fat absorption was studied by measuring fecal fat content. During the placebo and ultrahigh-viscosity phases, all subjects completed a 72-h stool collection on days 5, 6 and 7.
Long-term study Of the 40 subjects, 20 were women with mean age 41.6 (range, 27.3-55.9 , of ultra-high viscosity HPMC were compared with placebo for cholesterol-lowering ability in mildly hypercholesterolemic subjects, using a randomized, double-blinded, placebo-controlled, parallel design. HPMC was administered in a hot chocolate drink with breakfast (5 and 15 g day À1 treatment groups) and in sugarmolasses cookies with lunch and dinner (15 g day À1 treatment group). The cookie formulation is detailed in Swidan et al. (1996) . The number of subjects in each treatment group was determined by power calculations based on expected cholesterol-lowering efficacy at the two doses (estimated at B1% per g HPMC per day) and previously observed coefficients of variation in total cholesterol data. Although power calculations indicated that five subjects would be sufficient, 10 were enrolled for the 15 g HPMC per day group and 10 for the placebo Group, to take into account the lower hydration rate of HPMC in the cookies and the length of the study. Twenty subjects were enrolled for the 5 g HPMC per day group because the cholesterol-lowering effect was expected to be more modest.
The hot chocolate drink containing 5 g HPMC was not accepted by the subjects, who immediately complained vociferously about its non-palatability and threatened to abandon the study at the end of week 1. Subsequently, a 1-week washout period was invoked for all subjects (week 2) and, beginning with week 3, all test subjects received the 5 g HPMC decreases serum cholesterol C Reppas et al HPMC cookie formulation in lieu of the 5 g HPMC-hot chocolate drink at breakfast. Subjects receiving the placebo were switched to a placebo cookie in lieu of the placebo hot chocolate to maintain blinding. There were no subsequent complaints regarding palatability. The protocol for the longterm study is presented in Table 1 . The long-term study was an outpatient study, with subjects reporting daily to pick up their drink mix (week 1), cookies (weeks 1, 3-8) and any needed forms. Subjects consumed their usual meals along with the study formulations. Food and exercise diaries were recorded 1 week before the study, and during weeks 1, 4 and 8. Compliance with the consumption of the test formulations was assessed daily.
Analysis of samples and questionnaire
Biochemical and lipid measurements were performed at the Clinical Laboratories of The University of Michigan Hospitals, using a validated method exhibiting 1% variation in total cholesterol (TC) concentration within sample, and 2.2% variation between days. LDL-C was calculated from the TC, high-density lipoprotein cholesterol (HDL-C) and TG concentrations using the formula:
Stool collections were analyzed by the Mayo Clinic (Rochester, MN, USA) using an NMR-based procedure involving microwave drying, followed by estimation of percent solid and percent fat via signal analysis of the remaining protons (Van de Kamer, 1958) . Compared with the established, standard gravimetric method, values for percent solid and fat content differed by 2 and 6%, respectively.
Questionnaires regarding adverse effects were completed on day 1 of both trials, on day 7 of each phase of the mechanism study and on day 7 during weeks 1, 3 and 6 in the long-term study. Subjects scored headache, palpitations, dizziness, bloating, gastrointestinal discomfort, abdominal cramps, diarrhea and flatulence as follows: no effect (0), mild effect (1 ¼ less than 30 min, 2 ¼ more than 30 min), moderate effect (3 ¼ less than 30 min, 4 ¼ more than 30 min) and severe effect (5 ¼ less than 30 min and 6 ¼ more than 30 min). Space was also provided for subjects to record other adverse effects.
Bowel movement number and consistency were reported on days 5, 6 and 7 of the placebo and ultra-high-viscosity phases of the mechanism study. Bowel movement consistency was scored as follows: 1 (liquid), 2 (loose, soft, fragmented stools), 3 (soft but continuous stool), 4 (firm stool) or 5 (difficulty in passage due to rigidity).
Statistical analysis
In the mechanism study, all measures, except fecal fat, were tested for significant differences with repeated measures analysis of variance (SuperAnova, Abacus Concepts, Berkeley, CA, USA) using Tukey's Compromise as a post hoc test. Fecal fat data were analyzed with the paired t-test.
In the long-term study, data were treated with univariate (for example the unadjusted univariate f-statistic) and multivariate (for example Wilks Lambda) repeated measures analysis of variance using an SAS Statistical Analysis Package (SAS Institute Inc., Cary, NC, USA). The two approaches gave similar results. Factors analyzed were week (within-subject) and treatment group, gender and age (between subjects). The null hypotheses were that no week, week-by-gender, weekby-age or week-by-group interactions existed.
All differences were considered significant at the 95% confidence level.
Results

Mechanism study
Differences among day 1 of placebo and treatment phases were not significant for any index, indicating that the 1-week wash-out period between phases was adequate. Serum lipoprotein data (mean7s.e.m. values) are presented in Table 2 .
Total cholesterol values differed significantly between days 1 and 8 (P ¼ 0.0001) for the treatment phases and among phases on day 8 (P ¼ 0.0001). The interaction between days and groups was significant (P ¼ 0.0020). Total cholesterol was lower at day 8 than day 1 for the medium-viscosity (10.1%), high-viscosity (15.8%) and ultra-high viscosity (15.6%) phases. In contrast, values on days 1 and 8 of the placebo phase did not significantly differ. Total cholesterol on day 8 for each test phase was lower (P ¼ 0.0001) than in the day 8 placebo phase (9.3% for medium-viscosity, 16.9% for HPMC decreases serum cholesterol C Reppas et al high-viscosity and 13.8% for ultra-high-viscosity phases). Total cholesterol on day 8 for the high-viscosity and ultrahigh-viscosity phases were significantly lower than the corresponding concentrations on day 8 for the mediumviscosity phase, by 8.3 and 4.9%, respectively. There was no significant difference at day 8 between the high-viscosity and ultra-high-viscosity phases. LDL-cholesterol differed between days 1 and 8 (P ¼ 0.0004) for the treatment phases and among phases on day 8 (P ¼ 0.0005), with significant interactions between day and viscosity phase (P ¼ 0.003). Day 8 levels were 10.6% lower than day 1 in the medium-viscosity, 18.2% lower in the high-viscosity and 17.0% lower in the ultra-high-viscosity phase. No significant difference was observed between days 1 and 8 for the placebo phase. LDL-cholesterol was significantly different among day 8 (P ¼ 0.0001) of the test and placebo phases, with 15.3, 23.5 and 19.4% reductions in the medium-, high-and ultra-high-viscosity phases, respectively. On day 8, LDL-cholesterol in the high-viscosity phase was significantly lower (9.7%) than the corresponding mediumviscosity phase; however, differences between the highviscosity and ultra-high-viscosity phases were not significant.
HDL-cholesterol values did not differ significantly among phases on day 8 (P ¼ 0.7) or between days 1 and 8 (P ¼ 0.2) for the treatment or placebo phases. The interaction between days and viscosity phases was of borderline significance (P ¼ 0.0495). Post hoc analysis revealed a significant decrease (7.5%) between days 1 and 8 only for the ultra-high-viscosity phase.
Values for triglycerides did not differ between phases (P ¼ 0.14), but they did differ between days (P ¼ 0.0173) and tended to decrease between days 1 and 8. The interaction between days and groups was not significant, nor did triglycerides differ at day 8 among the treatment phases.
Adverse effects (Table 3 ) on day 7 of each treatment phase differed only for flatulence (P ¼ 0.0018), bloating (P ¼ 0.0040) and headache (P ¼ 0.0151). Post hoc analysis indicated that these three effects differed in all treatment phases from the placebo phase, but not among treatment phases. Headaches scored more favorably in the HPMC phases. Other adverse effects (palpitations, dizziness, gastrointestinal discomfort, abdominal cramps and diarrhea) did not vary with phase (P-values always 40.0975), and mean scores were at most 1.1.
The number and consistency of bowel movements did not vary with recording day within any phase (P ¼ 0.3, number; P ¼ 0.8, consistency). The number of bowel movements was different among phases (P ¼ 0.0001) ( Table 3) . Post hoc analysis showed significant differences between test phases and placebo phase. More bowel movements were recorded during the high-viscosity than the ultra-high-viscosity phase. Stool consistency did not differ among phases (P ¼ 0.0878). Total stool weight per day was 78% greater in the ultrahigh-viscosity phase than in the placebo phase (P ¼ 0.003, paired t-test). Grand mean values (that is, values averaged for days and subjects) were 7327333 g for the ultra-highviscosity phase and 4117244 g for the placebo phase. Analogously, fat in the total stool per day was 83% higher in the ultra-high-viscosity phase (4.471.9 g) than in the placebo phase (2.471.2 g) (P ¼ 0.001). These values remain within the normal range (0-7 g) for fecal fat per day. The percentage of fat in the total stool solids was 1274% in the ultra-high-viscosity phase and 1073% in the placebo phase (P ¼ 0.065, not significant). Long-term study Owing to the parallel design, the results are presented as percent lipid reduction within each group rather than against placebo. The absolute mean7s.e.m. values (mmol l À1 and mg dl À1 ) for total cholesterol, LDL-cholesterol, HDLcholesterol and triglycerides are presented in Table 4 . One-week ultra-high viscosity HPMC treatment (hot drink and cookie) Hydroxypropylmethylcellulose effectively lowered total (6%, P ¼ 0.0001) and LDL-cholesterol (8%, P ¼ 0.0003) at an intake of ultra-high viscosity HPMC of 5 g day À1 , and decreased both total (P ¼ 0.0121) and LDL-cholesterol (P ¼ 0.0056) 8% at 15 g day À1 . HDL-cholesterol, triglycerides and the LDL\HDL ratio did not significantly differ from baseline for either group (except for a 9% reduction in HDL-cholesterol in the 5 g day À1 group, P ¼ 0.0002). Complete 8-week data Baseline data obtained immediately before week 1 were compared with data at the end of week 8. Repeated measures analysis of variance indicated significant lowering of total and LDL-cholesterol levels in terms of a week by group effect (Po0.008 in all comparisons). Levels in the 5 g day À1 group (Po0.05 for total and Po0.002 for LDL-cholesterol) and the 15 g day À1 group (total cholesterol P ¼ 0.0001; LDL-cholesterol P ¼ 0.0001) were lower than in the placebo group. Additionally, levels in the 15 g day À1 group were lower than those in the 5 g day À1 group (total cholesterol P ¼ 0.01; LDL-cholesterol P ¼ 0.002).
Discussion
Mechanism study The mechanism study tested whether the ability of HPMC to decrease serum cholesterol is related to generation of high viscosity in aqueous solution. Increasing the gelatin dessert viscosity from 1 to 23 000 cP decreased total and LDLcholesterol without decreasing HDL-cholesterol. Increasing viscosity to 63 000 cP produced no additional benefit. The results for the high-viscosity (B23 000 cP) HPMC were commensurate with an earlier report (Dressman et al., 1993) . HPMC's cholesterol-lowering ability shows an associative relationship with creation of a viscous environment. The medium-viscosity HPMC, which may be easiest to formulate into foods, was able to lower total and LDL-cholesterol significantly at 15 g day
À1
. Higher viscosity grades of HPMC were even more effective, though no difference was observed between the high-and ultra-high viscosity HPMCs. This may be attributable to (1) having already reached maximum luminal viscosity with the high-viscosity HPMC and/or (2) an insufficient difference in viscosity between the high-and ultra-high viscosity grades: the viscosity of high-viscosity HPMC is 5.8 times higher than that of medium-viscosity HPMC, while the factor for ultra-high to high viscosity HPMC is only 2.8.
The mechanism study also addressed possible disruption of fat digestion by HPMC. HPMC increased the number of bowel movements but not stool consistency. The 83% increase in stool fat suggests that 2% ultra-high viscosity (15 g day À1 ) may hinder liquefied fat assimilation, possibly by hindering fat digestion, binding fat molecules and/or decreasing fat diffusivity towards the gastrointestinal mucosa. However, the increase of stool fat was commensurate with total stool output, and the percentage of stool fat remained unchanged. This finding suggests that the effects were mechanical in nature rather than involving a specific binding mechanism.
As reported in previous studies (Swidan et al., 1996; Maki et al., 1999 Maki et al., , 2000 , HPMC caused only mild gastrointestinalrelated adverse effects. Regardless of viscosity, it can be concluded that a 1-week administration of HPMC (15 g day À1 ) resulted in only mild to moderate flatulence and mild bloating.
Long-term study A significant difference was noted for total and LDLcholesterol between the start and end of the 8-week trial (see Table 4 ), with reductions evident after 1 week and being maintained throughout the treatment periods. There was a slight, unexpected upturn in the total, LDL-and HDLcholesterol levels in the 15 g day À1 group between weeks 7 and 8 (Table 4) . The s.e.m. values indicate that these increases did not affect the significance of the total and LDL-cholesterol reductions. Results for the 5 g day À1 and placebo groups were unchanged between weeks 7 and 8. The long-term study supports results from an earlier study (Maki et al., 1999) in which high-viscosity HPMC was administered in an orange drink over a 6-week period, albeit at lower doses In that study, 5 and 7.5 g day
, but not 2.5 g day
, reduced both total and LDL-cholesterol, suggesting the existence of a threshold. Provided the 'dosage form' is palatable, it appears to be possible to administer the HPMC effectively as either a drink or a solid comestible.
Concluding remarks
Cholesterol reduction with b-glucan, guar and psyllium is in the 5-10% range, but their 'dosage to efficacy' ratio is higher than for HPMC. The FDA approved the claim that about 10 g of psyllium per day lowers LDL-cholesterol 4.2% (Spiller, 1994) . For oat-based b-glucan, the approved claim is for consumption of X40 g oat bran or X60 g oatmeal per day, which reportedly reduces LDL-cholesterol 5% (United States Food and Drug Administration, 1997). By contrast, as little as 5 g day À1 HPMC lowered LDL-cholesterol about 10% with minor adverse effects, indicating that HPMC administration is an efficient and well-tolerated way of achieving reductions in cholesterol in mildly hypercholesterolemic subjects.
